Key Highlights
- Grant of Awards: iX Biopharma Ltd. has announced the grant of 9,400,892 ordinary shares under its iX Performance Share Plan (iX PSP).
- Date of Award: The awards were granted on 8 May 2026.
- Recipient Group: The awards are granted to employees of the Company, specifically excluding the Chairman & CEO.
- Market Price: The closing price of iX Biopharma shares on the date of the award was S\$0.41 per share.
- Vesting Schedule: The awards will vest in tranches over the next two years. No consideration is payable by recipients for the grant of the awards.
- Director and Controlling Shareholders: No shares have been awarded to any Director or controlling shareholder, nor their associates.
Detailed Award Schedule
| Vesting Date | Number of Shares Vested |
|---|---|
| On Date of Award (8 May 2026) | 2,955,853 shares |
| 28 February 2027 | 2,072,520 shares |
| 8 May 2027 | 2,300,000 shares |
| 29 February 2028 | 2,072,519 shares |
| Total | 9,400,892 shares |
Important Information for Shareholders
- Potential Share Dilution: The issuance of 9.4 million new shares could result in dilution for existing shareholders. Investors should consider the impact on earnings per share and voting power.
- Employee Incentives: The Performance Share Plan is designed to incentivize and retain talent. The exclusion of the Chairman & CEO ensures that the awards are focused on other staff, which may align interests and reward performance.
- Price Sensitivity: The grant of a large number of shares at S\$0.41 (the closing price on grant date) and their scheduled vesting could potentially affect the share price, especially as tranches vest and employees may decide to sell.
- No Director or Controlling Shareholder Participation: The absence of awards to directors and controlling shareholders avoids conflicts of interest and may be viewed positively by minority shareholders.
- Market Announcement Compliance: This announcement follows compliance with Rule 704(32) of SGX Catalist, ensuring transparency and market confidence.
- Sponsor Oversight: The announcement has been reviewed by UOB Kay Hian Private Limited, although the SGX-ST has not examined or approved the contents.
Potential Impact on Share Price
The grant of nearly 9.4 million shares under the iX Performance Share Plan introduces possible short- and mid-term volatility in the share price, mainly due to dilution and the staggered vesting schedule. As each tranche vests, employees may sell their shares, increasing supply in the market. Additionally, this award structure signals a commitment to rewarding performance and retaining key talent, which could be interpreted positively by investors focused on long-term growth.
Investors should closely monitor the vesting dates as potential periods of increased share activity. The structure and purpose of the awards, as well as the exclusion of senior executives, suggest alignment with shareholder interests and prudent corporate governance.
Contact Information
For further queries, shareholders may contact the Sponsor’s representative, Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Shareholders and prospective investors should conduct their own research and consult with qualified professionals before making any investment decisions. The Singapore Exchange Securities Trading Limited has not examined or approved the contents of this article, and assumes no responsibility for its accuracy.
